Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.56 |
| ▸ | CASP2 | P42575 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 4/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117197 | 0.94 | DNM1 (0.65) | DNM1CASP2FAAHNAAAHDAC3 | |
| SCHEMBL13826993 | 0.92 | DNM1 (0.68) | DNM1CASP2FAAHNAAAHDAC3 | |
| SCHEMBL30632366 | 0.92 | DNM1 (0.68) | DNM1CASP2FAAHNAAAHDAC3 | |
| SCHEMBL5495532 | 0.92 | DNM1 (0.68) | DNM1CASP2FAAHNAAAHDAC3 | |
| SCHEMBL5503356 | 0.92 | DNM1 (0.68) | DNM1CASP2FAAHNAAAHDAC3 | |
| SCHEMBL10494183 | 0.92 | DNM1 (0.68) | DNM1CASP2FAAHNAAAHDAC3 | |
| SCHEMBL9001775 | 0.92 | DNM1 (0.68) | DNM1CASP2FAAHNAAAHDAC3 | |
| SCHEMBL3113940 | 0.86 | — | — | |
| SCHEMBL11955684 | 0.86 | HDAC3 (0.61) | DNM1CASP2FAAHHDAC3HDAC4 | |
| SCHEMBL14576902 | 0.86 | CASP2 (0.64) | DNM1CASP2FAAHNAAACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8460445-B2 | Corrosion protection coatings | BASF SE (DE) | 2013-06-11 | — | — | US | claimed |
| CN-101711269-B | Anticorrosive paint | BASF SE | 2013-05-15 | — | — | CN | claimed |
| US-20120227618-A1 | CORROSION PROTECTION COATINGS | BASF SE (DE) | 2012-09-13 | — | — | US | claimed |
| US-20100175583-A1 | CORROSION PROTECTION COATINGS | BASF SE (DE) | 2010-07-15 | — | — | US | claimed |
| CN-101711269-A | Anticorrosive paint | BASF SE | 2010-05-19 | — | — | CN | claimed |
| US-20230390308-A1 | URSODEOXYCHOLIC ACID DERIVATIVES FOR THE TREATMENT OF POLYCYSTIC DISEASES | UNIV DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2023-12-07 | — | — | US | disclosed |
| US-11833160-B2 | Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases | UNIVERSIDAD DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2023-12-05 | — | — | US | disclosed |
| EP-4219516-A2 | CHIRAL CONTROL | Wave Life Sciences Ltd. (SG) | 2023-08-02 | — | — | EP | disclosed |
| EP-3733684-B9 | URSODEOXYCHOLIC ACID DERIVATIVES FOR THE TREATMENT OF POLYCYSTIC DISEASES | UNIV DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2022-05-11 | — | — | EP | disclosed |
| EP-3733684-B1 | URSODEOXYCHOLIC ACID DERIVATIVES FOR THE TREATMENT OF POLYCYSTIC DISEASES | UNIV DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2022-01-26 | — | — | EP | disclosed |
| EP-3041904-B1 | STYRYL SULFIDE DYES | BASF SE (DE) | 2020-05-20 | — | — | EP | disclosed |
| US-20130186300-A1 | CORROSION PROTECTION COATINGS | ROSCHMANN KONRAD (DE) | 2013-07-25 | — | — | US | disclosed |
| US-7022825-B2 | Polyketides and antibiotics | KOSAN BIOSCIENCES, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | ASHLEY GARY (US) | 2003-05-22 | — | — | US | disclosed |
| US-20030092140-A1 | Novel polyketides and antibiotics | ASHLEY GARY (US) | 2003-05-15 | — | — | US | disclosed |
| US-6492562-B1 | INVENTION ALSO RELATES TO NOVEL INTERMEDIATES AND THE RESULTING MODIFIED POLYKETIDES AND ANTIBIOTICS. | KOSAN BIOSCIENCES, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1144375-A2 | SYNTHESIS OF OLIGOKETIDES | Kosan Biosciences (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000044717-A9 | SYNTHESIS OF OLIGOKETIDES | — | 2001-08-23 | — | — | WO | disclosed |
| WO-2000044717-A2 | SYNTHESIS OF OLIGOKETIDES | KOSAN BIOSCIENCES, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| US-5015767-A | Reducing agents for hair | SOCIETE ANONYME DITE: L'OREAL (FR) | 1991-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390308-A1 | URSODEOXYCHOLIC ACID DERIVATIVES FOR THE TREATMENT OF POLYCYSTIC DISEASES | PKD1, PKD2, SLC10A1 | DNM1 527/4885CASP2 2398/4885FAAH 3038/4885 |
| US-11833160-B2 | Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases | HDAC1, HDAC2, HDAC9 | DNM1 2054/4885CASP2 1080/4885FAAH 2914/4885 |
| US-20100175583-A1 | CORROSION PROTECTION COATINGS | MGMT, SOD1, SOD3 | DNM1 1546/4885CASP2 908/4885FAAH 4746/4885 |
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | COASY, KARS1, ACOT7 | DNM1 4376/4885CASP2 2240/4885FAAH 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.